Inicio › Cánceres de la sangre › Distrito de Columbia › Washington
Ensayos clínicos de Cánceres de la sangre en Washington, DC
19 estudios para Cánceres de la sangre buscan participantes en centros de Washington y alrededores (a unos 30 millas). Abra un estudio para ver quién puede participar y cómo contactar con el equipo.
Texto oficial del estudio (inglés)
Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
ReclutandoFase 1
- MedStar Georgetown University Hospital, Washington D.C.
- National Cancer Institute Developmental Therapeutics Clinic, Bethesda · A 7 mi de distancia
Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies
ReclutandoFase 1
- National Institutes of Health Clinical Center, Bethesda · A 7 mi de distancia
Observational Study of Cardiac Arrhythmias During Treatment With BTK Inhibitors or Venetoclax
ReclutandoEstudio observacional
- National Institutes of Health Clinical Center, Bethesda · A 7 mi de distancia
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
ReclutandoEstudio observacionalSe aceptan voluntarios sanos
- MedStar Georgetown University Hospital, Washington D.C.
- MedStar Washington Hospital Center, Washington D.C.
- Walter Reed National Military Medical Center, Bethesda · A 7 mi de distancia
Trial of Allogeneic Reduced-Intensity, HLA-Haploidentical Allogeneic Hematopoietic Cell Bone Marrow Transplantation Followed by Graft-versus-Host-Disease (GVHD) Prophylaxis With Cyclophosphamide, Bortezomib and Maraviroc for Hematologic Malignancies ...
ReclutandoFase 1/2Se aceptan voluntarios sanos
- National Institutes of Health Clinical Center, Bethesda · A 7 mi de distancia
Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
ReclutandoFase 3
- American Oncology Partners, PA dba The Center for Cancer and Blood Disorders, Bethesda · A 7 mi de distancia
Phase I Trial Integrating HLA-Haploidentical Anti-CD19 CAR-T Cells With Post-Transplantation Cyclophosphamide-Based HLA-Haploidentical Hematopoietic Cell Transplantation
ReclutandoFase 1
- National Institutes of Health Clinical Center, Bethesda · A 7 mi de distancia
Donor Lymphocyte Infusion After Allogeneic Hematopoietic Cell Transplantation for High-Risk Hematologic Malignancies
ReclutandoFase 1/2Se aceptan voluntarios sanos
- National Institutes of Health Clinical Center, Bethesda · A 7 mi de distancia
Longitudinal Studies of Patient With FPDMM
ReclutandoEstudio observacionalSe aceptan voluntarios sanos
- National Institutes of Health Clinical Center, Bethesda · A 7 mi de distancia
The Lowest Effective Dose of Post-Transplantation Cyclophosphamide in Combination With Sirolimus and Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis After Reduced Intensity Conditioning and Peripheral Blood Stem Cell Transplantation
ReclutandoFase 1/2Se aceptan voluntarios sanos
- National Institutes of Health Clinical Center, Bethesda · A 7 mi de distancia
A Longitudinal Multi-Center Molecular Biomarker Discovery Registry for Patients With Hematologic Malignancies
ReclutandoEstudio observacional
- The Center for Cancer and Blood Disorders, Bethesda · A 7 mi de distancia
Multi-institutional Prospective Research of Expanded Multi-antigen Specifically Oriented Lymphocytes for the Treatment of VEry High Risk Hematopoietic Malignancies
ReclutandoFase 1
- Childrens National Medical Center, Washington D.C.
Mosaic Trial for Stem Cell Transplant Recipients
Reclutando
- Georgetown University School of Medicine, Washington D.C.
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
ReclutandoEstudio observacional
- Children's National Medical Center, Washington D.C.
- Nih/Niaid, Bethesda · A 7 mi de distancia
- Nih/Nhlbi, Bethesda · A 7 mi de distancia
Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies
ReclutandoFase 1/2
- The Center for Cancer and Blood Disorders (CCBD), Bethesda · A 7 mi de distancia
Phase I/II Study to Reduce Post-transplantation Cyclophosphamide Dosing for Older or Unfit Patients Undergoing Bone Marrow Transplantation for Hematologic Malignancies
ReclutandoFase 1/2Se aceptan voluntarios sanos
- National Institutes of Health Clinical Center, Bethesda · A 7 mi de distancia
Collecting Blood and Tissue Sample Donations for Research for HIV/AIDS-Related Cancers
ReclutandoEstudio observacional
- George Washington University, Washington D.C.
Natural History Study to Determine Drug Metabolism Phenotype and Appropriate Germline Source DNA in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant
ReclutandoEstudio observacionalSe aceptan voluntarios sanos
- National Institutes of Health Clinical Center, Bethesda · A 7 mi de distancia
Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
ReclutandoFase 1
- Children's National Medical Center, Washington D.C.
- National Cancer Institute, Pediatric Oncology Branch, Bethesda · A 7 mi de distancia
Ensayos de Cánceres de la sangre en otras ciudades
- Houston, TX46 estudios
- New York City, NY26 estudios
- Boston, MA25 estudios
- Seattle, WA18 estudios
- Baltimore, MD18 estudios
- Los Angeles, CA17 estudios
- Durham, NC16 estudios
- Chicago, IL15 estudios
- Philadelphia, PA14 estudios
- Nashville, TN13 estudios
- Edison, NJ13 estudios
- Columbus, OH13 estudios
Otros estudios en Washington
- Cáncer (todos los tipos)58 estudios
- Cáncer de pulmón de células no pequeñas55 estudios
- Cáncer de seno46 estudios
- Cáncer metastásico43 estudios
- Cáncer de pulmón41 estudios
- Cáncer de próstata38 estudios
- Obesidad33 estudios
- Cáncer del colon y del recto29 estudios
- Enfermedad cardiovascular28 estudios
- Cáncer de vejiga26 estudios
- Leucemia mielógena aguda24 estudios
- Cáncer de ovario23 estudios
De ClinicalTrials.gov, datos obtenidos el 6 oct 2026. Cada estudio establece sus propios criterios de elegibilidad; el equipo del estudio decide quién puede participar.